Fuss Brands Corp. Signs Licensing Agreement with Anyvention Ltd. to Acquire Intellectual Property Rights
NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fuss Brands Corp. (OTC Markets: FBDS) announced today the signing of an...
Day: November 4, 2022
Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
THE WOODLANDS, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2022...
VitalHub Corp. Announces Acquisition of Certain Assets to Maintain the Business of ADI Health
TORONTO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) (OTCQX:VHIBF) is pleased to announce...
Nanomix Enters into Multi-Country Distribution Agreement for the eLab System with Mast Group Limited
SAN LEANDRO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development...
AUM Biosciences to Participate in BioCentury-BayHelix East-West BioPharma Summit
SINGAPORE and BETHESDA, Md., Nov. 04, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing...
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
EDISON, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial...
Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022
Data demonstrated treatment with TERN-501 resulted in time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker...
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a...
OrthoPediatrics to Participate in Upcoming November Conferences
WARSAW, Ind., Nov. 04, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on...
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and...
ORYZON to Give Updates on Corporate Progress in November
Kabuki Syndrome Foundation Annual Conference11th Drug Discovery Strategic SummitInv€$tival Showcase LSX Leaders 2022Jefferies London Healthcare Conference 2022MADRID, Spain and BOSTON,...
Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection
Six-month outcomes are expected in second quarter of 2023DALLAS, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a...
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference
Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference...
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points...
CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022
NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and...
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
--Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3...
Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. is re-issuing its earnings press release for the third...
Rain Therapeutics Announces $50 Million Registered Offering of Common Stock
NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision...
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase...
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject...